TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02120781

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Azficel-T (autologous fibroblasts)
Description: Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.~Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
Study: NCT02766946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromyopathy score
Description: A neuromyopathy score will be assessed on the extubation day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory performances
Description: An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory performances
Description: An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory performances
Description: An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
Study: NCT02588313

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mango fruit powder
Description: Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mango fruit powder
Description: Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mango fruit powder
Description: Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
Study: NCT03199014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deploying the Drug-eluting Stents with a prolonged time
Description: the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deploying the Drug-eluting Stents with a conventional time
Description: the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
Study: NCT01925014

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic CT with low-dose radiation
Description: Effective dose is aimed at approximately 2 millisievert (mSv) in an average patient.
Study: NCT00620087

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening Mammography
Description: A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
Study: NCT01832779

Intervention type: OTHER
Intervention: Achalasia subjects
Description: Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
Study: NCT04635293

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative infusion of levosimendan
Description: the study group will consist of patients who have received a continuous infusion of levosimendan 0.1 μg/kg/min for 24 hours before cardiac surgery
Study: NCT01925014

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic CT with standard-dose radiation
Description: Effective dose is aimed at approximately 8 millisievert (or less) in an average patient.
Study: NCT00706264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicon ring (Arabin Pessary)
Description: Placement of a silicon pessary in the vagina, around the cervix.
Study: NCT00372489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
Study: NCT05148429

Intervention type: OTHER
Intervention: Ultrasound exam
Description: Ultrasound exam

Intervention type: OTHER
Intervention: Fetal MRI
Description: Fetal MRI

Intervention type: OTHER
Intervention: Postnatal abdominal ultrasound
Description: Postnatal abdominal ultrasound

Intervention type: OTHER
Intervention: Pediatric Follow up
Description: Pediatric Follow up
Study: NCT01511640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 2x daily for duration of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 2x daily for duration of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 2x daily for duration of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 2x daily for duration of study
Study: NCT01251991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psyllium husks
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Study: NCT04635293

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no preoperative infusion of levosimendan
Description: the control group will consist of patients who proceeded to the cardiac operation without any infusion for 24 hours preoperatively
Study: NCT00699283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: 25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
Study: NCT02757898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biotin-Labeled Red Blood Cells (RBCs)
Description: 500 mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.~For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.~For participants 3 through 8, the RBCs will be stored at 2-6 C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.~Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs.
Study: NCT04650191

Intervention type: OTHER
Intervention: Identification of genetic variants
Description: DNA will be extracted from whole blood from study subjects
Study: NCT01251991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psyllium husks
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isolated soy protein
Description: Oral suspension, oral use, 30 grams once per day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isolated soy protein
Description: Oral suspension, oral use, 30 grams once per day
Study: NCT04650191

Intervention type: OTHER
Intervention: Identification of genetic variants
Description: DNA will be extracted from whole blood from study subjects

Intervention type: OTHER
Intervention: Identification of genetic variants
Description: DNA will be extracted from whole blood from study subjects
Study: NCT00699283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: 25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
Study: NCT04077918

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: protein diet
Description: 100 CHD patients will be recruited and randomized into 2 groups with an additional animal or plant protein 18g per day
Study: NCT02685566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFDM Plus DBT
Description: FujiFilm Aspire Cristalle System
Study: NCT00588406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: 2mg/dose by nebulizer, four doses over 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: 2.5mg/dose by nebulizer, 7 doses over 6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol
Description: 2.5mg/dose by nebulizer, 7 doses over 6 hours
Study: NCT01251991

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Isolated whey protein
Description: Oral suspension, oral use, 30 grams once per day
Study: NCT00588406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: 2.5 mg, one dose
Study: NCT02685566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFDM
Description: FujiFilm Aspire Cristalle System
Study: NCT01661751

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACYW135 Meningococcal Polysaccharide Vaccine
Description: 600 subjects were divided into three groups (200 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A+C Meningococcal Polysaccharide Vaccine
Description: 300 subjects were divided into three groups (100 subjects in each group), adult (16\~30 years of age), early youth (7\~15 years of age) and children (2\~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
Study: NCT05128864

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: High Tibial Osteotomy
Description: Surgery procedure - High Tibial Osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Tibial Osteotomy
Description: Surgery procedure - High Tibial Osteotomy
Study: NCT01251991

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Isolated whey protein
Description: Oral suspension, oral use, 30 grams once per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Oral suspension, oral use, two daily dosages consisting of 5 grams each
Study: NCT04281823

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Magnetic Resonance
Description: Patients will undergo various CMR techniques designed to assess cardiovascular structure and function, tissue characteristics, and flow.
Study: NCT04476108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT02448095

Intervention type: DRUG
Intervention: Ponatinib
Description: Observation of tolerability and safety profiles
Study: NCT00397631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
Description: Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.
Description: Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
Study: NCT03109444

Intervention type: DIAGNOSTIC_TEST
Intervention: Hip Ultrasound
Description: Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be \>50%.
Study: NCT02213081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulipristal
Description: Patient will take 15mg every other day, or every 4 days per week.
Study: NCT00471276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: sunitinib (Sutent), 37.5 mg, daily dosing
Study: NCT03542292

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: placental drainage

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: placental drainage
Study: NCT00717951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxol, cisplatin, capecitabine
Description: docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxol, cisplatin, capecitabine
Description: docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
Study: NCT01537523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: community-care program
Description: community nurse care, physiotherapy
Study: NCT00572065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.~Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated.
Study: NCT03944460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.
Study: NCT02805894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBTXR3 activated by IMRT only
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBTXR3 activated by Brachytherapy & IMRT
Description: Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy \& IMRT treatment
Study: NCT00952588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1152
Description: 1200 mg, iv, 7 day infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDAC
Description: 20 mg, sc, bd, 10 days
Study: NCT00606229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg/day
Study: NCT01110928

Intervention type: DRUG
Intervention: somatropin
Description: Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
Study: NCT03944460

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Contraloid
Description: Oral administration of capsules, drug substance or placebo without any excipients.
Study: NCT04474366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution
Description: Ropivacaine 0.2% Injectable Solution injected as part of the Pectoralis Nerve Block

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline (0.9%)
Description: Saline injection as sham block in identical fashion as Pectoralis Nerve Block
Study: NCT03773601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Profiler
Description: A 4-days sleep monitoring with the use of the Sleep Profiler. Data on objective sleep behavior will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSQI
Description: Fill the Pittsburgh Sleep Quality Index (PSQI) for the subjective evaluation of sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TQR
Description: Fill the Total Quality of Recovery Scale (TQR), every morning for 4 consecutive days, to collect data on subjective perception of recovery,
Study: NCT02139280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
Study: NCT01585909

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastroscopy
Description: When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
Study: NCT01224730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: perifosine
Description: 100 mg daily
Study: NCT01585909

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastroscopy
Description: When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Gastroscopy
Description: When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
Study: NCT02846766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
Study: NCT01119924

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Smilon®
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
Study: NCT00851318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate dose between 6 to 8 mg/week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate dose between 6 to 8 mg/week.
Study: NCT03411096

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block using ropivacaine
Description: After general anesthesia, an anesthesiologist will perform an quadratus lumborum block with 0.75% ropivacaine (20cc) under ultrasound guidance.
Study: NCT01119924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks